Literature DB >> 25511779

Multi-kinase inhibitors.

Laura Garuti, Marinella Roberti, Giovanni Bottegoni1.   

Abstract

The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action. An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect. Moreover, this approach can reduce the possibility of developing drug resistance. Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homology among the ATP-binding site of kinases. In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands. Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket. In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chemical structures, structure-activity relationship (SAR) and biological activity. These inhibitors, suitably substituted, could be used in designing other multitarget agents. Virtual molecular docking would suggest potential targets of molecules, moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25511779     DOI: 10.2174/0929867321666141216125528

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  Development of Pyrazolo[3,4-d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.

Authors:  Chiara Greco; Vincenzo Taresco; Amanda K Pearce; Catherine E Vasey; Stuart Smith; Ruman Rahman; Cameron Alexander; Robert J Cavanagh; Francesca Musumeci; Silvia Schenone
Journal:  ACS Med Chem Lett       Date:  2020-02-13       Impact factor: 4.345

Review 2.  Protein Kinase Targets in Breast Cancer.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Int J Mol Sci       Date:  2017-11-27       Impact factor: 5.923

3.  Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.

Authors:  Riyo Morimoto-Kamata; Satoru Yui
Journal:  Cancer Sci       Date:  2017-06-21       Impact factor: 6.716

4.  Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.

Authors:  Dilip Narayanan; Osman A B S M Gani; Franz X E Gruber; Richard A Engh
Journal:  J Cheminform       Date:  2017-07-04       Impact factor: 5.514

5.  Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.

Authors:  Yung Chang Hsu; Mohane Selvaraj Coumar; Wen-Chieh Wang; Hui-Yi Shiao; Yi-Yu Ke; Wen-Hsing Lin; Ching-Chuan Kuo; Chun-Wei Chang; Fu-Ming Kuo; Pei-Yi Chen; Sing-Yi Wang; An-Siou Li; Chun-Hwa Chen; Po-Chu Kuo; Ching-Ping Chen; Ming-Hsine Wu; Chen-Lung Huang; Kuei-Jung Yen; Yun-I Chang; John T-A Hsu; Chiung-Tong Chen; Teng-Kuang Yeh; Jen-Shin Song; Chuan Shih; Hsing-Pang Hsieh
Journal:  Oncotarget       Date:  2016-12-27

6.  Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor.

Authors:  Luyao Wang; Lin Wang; Magdalena Cybula; Ana Luiza Drumond-Bock; Katherine M Moxley; Magdalena Bieniasz
Journal:  Genes Cancer       Date:  2020-07-22

7.  Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies.

Authors:  Wagdy M Eldehna; Sara T Al-Rashood; Tarfah Al-Warhi; Razan O Eskandrani; Amal Alharbi; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

8.  On the development of B-Raf inhibitors acting through innovative mechanisms.

Authors:  Luca Pinzi
Journal:  F1000Res       Date:  2022-02-25

9.  Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.

Authors:  Chae Young Hwang; Su Jong Yu; Jae-Kyung Won; Sang-Min Park; Jung-Hwan Yoon; Kwang-Hyun Cho; Hyojin Noh; Soobeom Lee; Eun Ju Cho; Jeong-Hoon Lee; Kyung Bun Lee; Yoon Jun Kim; Kyung-Suk Suh
Journal:  Cancer Gene Ther       Date:  2021-08-06       Impact factor: 5.854

10.  Highly Antiproliferative Latonduine and Indolo[2,3-c]quinoline Derivatives: Complex Formation with Copper(II) Markedly Changes the Kinase Inhibitory Profile.

Authors:  Christopher Wittmann; Felix Bacher; Eva A Enyedy; Orsolya Dömötör; Gabriella Spengler; Christian Madejski; Jóhannes Reynisson; Vladimir B Arion
Journal:  J Med Chem       Date:  2022-02-01       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.